MDL 2924 (S.D. Fla., Judge Robin L. Rosenberg) omnibus Daubert order (Doc 6120, 341 pages): ALL defendants' Daubert motions on general causation GRANTED and defendants' summary judgment motion GRANTED — plaintiffs 'fail to produce admissible primary evidence of general causation' that ranitidine causes cancer, ending the federal MDL claims.

Related news

1. Jul 25, 2026

   Zantac / Ranitidine (NDMA Cancer)

   Public Search Interest in Zantac and NDMA Terms Rises Sharply

   Google Trends data recorded a sharp week-over-week rise in searches for 'ranitidine' (+300%), 'zantac lawsuit attorneys' (+150%), and 'ndma' (+170%), along with breakout search activity for 'zantac lawsuit update 2022,' 'cetirizine recall,' and 'recall on zantac.'

   Source: trends.google.com

2. Jul 24, 2026

   Zantac / Ranitidine (NDMA Cancer)

   Public Search Interest in Zantac Lawsuit Topics Spikes

   Google Trends data detected sharp increases in searches for terms including 'ranitidine' (up 300%), 'zantac lawsuit attorneys' (up 150%), and 'ndma' (up 170%), along with breakout search activity for 'zantac lawsuit update 2022' and 'recall on zantac,' according to Google Trends.

   Source: trends.google.com

3. Jul 20, 2026

   Zantac / Ranitidine (NDMA Cancer)

   Sanofi agreed to pay more than $100 million to settle ~4,000 Zantac cancer suits in state courts outside Delaware — the first major resolution in the litigation, averaging more than $25,000 per claim per Bloomberg's reporting (republished by Insurance Journal, Apr 23, 2024; deal announced earlier that month).

   Sanofi agreed to pay more than $100 million to settle ~4,000 Zantac cancer suits in state courts outside Delaware — the first major resolution in the litigation, averaging more than $25,000 per claim per Bloomberg's reporting (republished by Insurance Journal, Apr 23, 2024; deal announced earlier that month). Sanofi denied liability; 70,000+ suits then remained, mostly in Delaware.

   Source: insurancejournal.com